Publications

Alzheimer’s Disease Other Publications

Alzheimer’s Disease Publications

Includes publications related to wholly owned assets and select publications related to partnered assets.

2024

Increasing Representation and Diversity in Clinical Trials of Alzheimer’s Disease: Recruitment of Ethnically Diverse Participants With Alzheimer’s Disease in the Phase 1 ASCENT Clinical Trials of PRX012.
Increasing Representation and Diversity in Clinical Trials of Alzheimer’s Disease: Recruitment of Ethnically Diverse Participants With Alzheimer’s Disease in the Phase 1 ASCENT Clinical Trials of PRX012.

Swanson C, Martényi F, Tooker RE, Masterman D, Fitzgerald C, Johnson A, Li L, Quinceno ME, Kinney GG, Garren H.

Presented at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024; October 29-November 1, 2024; Madrid, Spain and virtual.
Patient Considerations in the Development and Delivery of Novel Treatments for Alzheimer’s Disease: A Quantitative Survey.
Patient Considerations in the Development and Delivery of Novel Treatments for Alzheimer’s Disease: A Quantitative Survey.

Silber A, Athavale A, O’Hara M, Masterman D, Bajaj PS.

Presented at 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024; October 29-November 1, 2024; Madrid, Spain and virtual.
Phase 1 Single and Multiple Dose Clinical Trials (ASCENT-1 and ASCENT-2) for Dose-Finding of PRX012 in Participants With Biologically Confirmed Alzheimer’s Disease.
Phase 1 Single and Multiple Dose Clinical Trials (ASCENT-1 and ASCENT-2) for Dose-Finding of PRX012 in Participants With Biologically Confirmed Alzheimer’s Disease.

Swanson C, Martényi F, Tooker RE, Campbell BM, Johnson A, Li L, Quinceno ME, Zago WM, Kinney GG, Garren H.

Presented at the Alzheimer’s Association International Conference® (AAIC) 2024; July 28 August 1, 2024; Philadelphia, PA, USA and virtual.
US Infusion Center Capacity to Accommodate Anti-Amyloid Treatments for Alzheimer’s Disease: A Quantitative Survey.
US Infusion Center Capacity to Accommodate Anti-Amyloid Treatments for Alzheimer’s Disease: A Quantitative Survey.

Silber A, Athavale A, Kulkarni A, O’Hara M, Mattke S, Bajaj PS.

Value Health. 2024;27(6):S229.

2023

Immunological Response to Dual Aβ/Tau Vaccine PRX123 Surrogate and Effects on Brain Amyloid Plaques in Rapidly Depositing Transgenic Animal Model.
Immunological Response to Dual Aβ/Tau Vaccine PRX123 Surrogate and Effects on Brain Amyloid Plaques in Rapidly Depositing Transgenic Animal Model.

Tourino C, Trumble A, Louie L, Barbour RM, Kinney GG, Campbell BM, Zago W.

Alzheimers Dement. 2023;19(S24):e082687.
PRX005, a Novel Anti-MTBR Tau Monoclonal Antibody: Results From a First-in-Human Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study.
PRX005, a Novel Anti-MTBR Tau Monoclonal Antibody: Results From a First-in-Human Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study.

Martényi F, Campbell BM, Kinney GG, Lee J, Jin Y, Zago WM, Garren H.

Alzheimers Dement. 2023;19(S21):e074181. Partnership with BMS.
Binding Characteristics of Surrogate PRX012 Demonstrate Potent Engagement of Toxic Aβ Protofibrils and Robust Clearance of Pyroglutamate-Modified Aβ.
Binding Characteristics of Surrogate PRX012 Demonstrate Potent Engagement of Toxic Aβ Protofibrils and Robust Clearance of Pyroglutamate-Modified Aβ.

Campbell BM, Zhang G, Salmans J, Elmaarouf A, Tam S, Porat A, Skov M, Dolan PJ, Kinney GG, Zago WM.

Presented at the AD/PD™ Alzheimer’s disease and Parkinson’s disease Conference 2023; March 28-April 1, 2023; Gothenburg, Sweden and virtual.

2021

PRX012 Induces Microglia-Mediated Clearance of Pyroglutamate-Modified and -Unmodified Aβ in Alzheimer’s Disease Brain Tissue.
PRX012 Induces Microglia-Mediated Clearance of Pyroglutamate-Modified and -Unmodified Aβ in Alzheimer’s Disease Brain Tissue.

Tam S, Zhang G, Li L, Elmaarouf A, Salmans J, Skov M, Dolan P, Kinney GG, Campbell B, Zago WM.

Alzheimers Dement. 2021;17(S9):e057773.
Microtubule Binding Region (MTBR)-Specific Antibody PRX005 Prevents Pathological Tau Progression Via Blockade on Neuronal Internalization.
Microtubule Binding Region (MTBR)-Specific Antibody PRX005 Prevents Pathological Tau Progression Via Blockade on Neuronal Internalization.

Dolan PJ, Tam SJ, Nijjar T, Holden MR, Tourino C, Elmaarouf A, Thomas K, Li L, Prill H, Bard F, Zago W.

Presented at the AD/PD™ Alzheimer’s disease and Parkinson’s disease Conference 2021; March 9-14, 2021; virtual. Partnership with BMS

2020

Novel Amyloid Beta Monoclonal Antibodies With Superior Binding Properties: Potential for More Convenient Dosing and Greater Patient Access in Alzheimer’s Disease.
Novel Amyloid Beta Monoclonal Antibodies With Superior Binding Properties: Potential for More Convenient Dosing and Greater Patient Access in Alzheimer’s Disease.

Skov M, Barbour R, Dolan P, Elmaarouf A, Goldbach E, Holden M, Li L, Nijjar T, Prill H, Salmans J, Tam S, Thomas K, Tourino C, Bard F, Kinney GG, Zago W.

J Prev Alz Dis. 2020;7(S1):S105.
Development of a Dual Aβ/Tau Vaccine for the Prevention and Treatment of Alzheimer’s Disease.
Development of a Dual Aβ/Tau Vaccine for the Prevention and Treatment of Alzheimer’s Disease.

Barbour R, Elmaarouf A, Prill H, Thomas K, Bard F, Kinney G, Zago W.

J Prev Alz Dis. 2020;7(S1):S104-105.

Pre-2020

Vascular Alterations in PDAPP Mice After Anti-Aβ Immunotherapy: Implications for Amyloid-Related Imaging Abnormalities.
Vascular Alterations in PDAPP Mice After Anti-Aβ Immunotherapy: Implications for Amyloid-Related Imaging Abnormalities.

Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG.

Alzheimers Dement. 2013;9(5 Suppl):S105-115.
Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific.
Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012;32(8):2696-2702.
Sustained Levels of Antibodies Against Aβ in Amyloid-Rich Regions of the CNS Following Intravenous Dosing in Human APP Transgenic Mice.
Sustained Levels of Antibodies Against Aβ in Amyloid-Rich Regions of the CNS Following Intravenous Dosing in Human APP Transgenic Mice.

Bard F, Fox M, Friedrich S, Seubert P, Schenk D, Kinney GG, Yednock T.

Exp Neurol. 2012;238(1):38‑43.
Structural Correlates of Antibodies Associated With Acute Reversal of Amyloid Beta-Related Behavioral Deficits in a Mouse Model of Alzheimer Disease.
Structural Correlates of Antibodies Associated With Acute Reversal of Amyloid Beta-Related Behavioral Deficits in a Mouse Model of Alzheimer Disease.

Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, Comery TA, Diep L, Gill D, Johnson-Wood K, Goel A, Grantcharova K, Lee M, Li J, Partridge A, Griswold-Prenner I, Piot N, Walker D, Widom A, Pangalos MN, Seubert P, Jacobsen JS, Schenk D, Weis WI.

J Biol Chem. 2010;285(5):3417-3427.
Aβ42 Immunization in Alzheimer’s Disease Generates Aβ N-Terminal Antibodies.
Aβ42 Immunization in Alzheimer’s Disease Generates Aβ N-Terminal Antibodies.

Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P.

Ann Neurol. 2005;58(3):430-435.
Peripherally Administered Antibodies Against Amyloid Beta-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease.
Peripherally Administered Antibodies Against Amyloid Beta-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease.

Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T.

Nat Med. 2000;6(8):916-919.
Immunization With Amyloid-Beta Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse.
Immunization With Amyloid-Beta Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P.

Nature. 1999;400(6740):173-177.
Alzheimer-Type Neuropathology in Transgenic Mice Overexpressing V717F Beta-Amyloid Precursor Protein.
Alzheimer-Type Neuropathology in Transgenic Mice Overexpressing V717F Beta-Amyloid Precursor Protein.

Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J.

Nature. 1995;373(6514):523-527.
Amyloid Beta-Peptide Is Produced by Cultured Cells During Normal Metabolism.
Amyloid Beta-Peptide Is Produced by Cultured Cells During Normal Metabolism.

Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ.

Nature. 1992;359(6393):322-325.

OTHER PUBLICATIONS

Includes publications related to wholly owned assets and select publications related to partnered assets.

2024

vPRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose escalation study.
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose escalation study.

Suhr OB, Grogan M, Martins da Silva A, Karam C, Garcia-Pavia P, Drachman B, Zago W, Tripuraneni R, Kinney GG.

Amyloid. 2024 Oct 29:1-8. Partnership with Novo Nordisk.
Prasinezumab Slows Motor Progression in Rapidly Progressing Early-Stage Parkinson’s Disease.
Prasinezumab Slows Motor Progression in Rapidly Progressing Early-Stage Parkinson’s Disease.

Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Brockmann K, Svoboda H, Trundell D, Monnet A, Doody R, Fontoura P, Kerchner GA, Brundin P, Nikolcheva T, Bonni A, PASADENA Investigators, Prasinezumab Study Group.

Nat Med. 2024;30(4):1096-1103. Partnership with Roche.

2022

Trial of Prasinezumab in Early-Stage Parkinson’s Disease.
Trial of Prasinezumab in Early-Stage Parkinson’s Disease.

Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay J-P, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D’Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga S, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A, PASADENA Investigators, Prasinezumab Study Group.

N Engl J Med. 2022;387(5):421-432. Partnership with Roche.
Development of C-Terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies.
Development of C-Terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies.

Barbour R, Elmaarouf A, Holden M, Louie L, Prill H, Skov M, Tam S, Tourino C, Campbell B, Kinney GG, Zago W.

Presented at the AD/PD™ Alzheimer’s disease and Parkinson’s disease Conference 2022; March 15-20, 2022; Barcelona, Spain and virtual.

2021

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson’s Disease (PASADENA): Rationale, Design, and Baseline Data.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson’s Disease (PASADENA): Rationale, Design, and Baseline Data.

Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; and PASADENA Investigators and Prasinezumab Study Group.

Front Neurol. 2021;12:705407. Partnership with Roche.

Pre-2020

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG.

JAMA Neurol. 2018;75(10):1206-14. Partnership with Roche.
First-in-Human Assessment of PRX002, an Anti-α-Synuclein Monoclonal Antibody, in Healthy Volunteers.
First-in-Human Assessment of PRX002, an Anti-α-Synuclein Monoclonal Antibody, in Healthy Volunteers.

Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG.

Mov Disord. 2017;32(2):211-218. Partnership with Roche.
Novel Conformation-specific Monoclonal Antibodies Against Amyloidogenic Forms of Transthyretin
Novel Conformation-specific Monoclonal Antibodies Against Amyloidogenic Forms of Transthyretin

Higaki JN, Chakrabartty A, Galant NJ, Hadley KC, Hammerson B, Nijjar T, Torres R, Tapia JR, Salmans J, Barbour R, Tam SJ, Flanagan K, Zago W, Kinney GG.

Amyloid. 2016 Jun;23(2):86-97.